Treponema pallidum specific IgM haemagglutination test for serodiagnosis of syphilis

T SATO,* E KUBO,* M YOKOTA,* T KAYASHIMA,* AND T TOMIZAWA†

From the *Third Department of the Research Laboratories, Fujirebio Incorporation, and the †Wealmar Research Laboratory, Tokyo, Japan

SUMMARY The Treponema pallidum specific IgM haemagglutination (TP-IgM-HA) test uses erythrocytes sensitised with antiserum to human IgM to separate IgM from IgG in serum. Specific antitreponemal IgM captured in this way is detected by adding a second reagent comprising erythrocytes sensitised with T pallidum antigen. Eighty two serum samples from 82 patients with untreated syphilis, 521 samples from 73 patients with treated syphilis, and 1872 samples from people who did not have syphilis were examined by the 19S(IgM)-TPHA (T pallidum haemagglutination), IgM-FTA-ABS (fluorescent treponemal antibody absorbed), TP-IgM-ELISA (enzyme linked immunosorbent assay), and TP-IgM-HA tests for the presence of 19S(IgM) antibodies specific to treponemes. The sensitivity of the TP-IgM-HA test was 97.6% and the specificity was 99.7%.

We also traced IgM specific to treponemes in untreated patients with primary syphilis by four different tests. The TP-IgM-HA test results clearly reflected the effect of the treatment.

Introduction

The rapid plasma reagin card test (RPR),¹ the complement fixation test with the cardiolipin antigen (CLCF),² the fluorescent treponemal antibody absorption test (FTA-ABS),³ and the Treponema pallidum haemagglutination test (TPHA)⁴ cannot differentiate between patients with active syphilis and those who have been adequately treated. To make a diagnosis of syphilis and to monitor the effect of treatment, several serological tests are performed. These tests are not standardised, however, and their performance is not uniform.

The importance of the treponemal 19S(IgM) diagnostic tests on patients with syphilis has been pointed out by several workers.⁵⁻⁸ O'Neill used the IgM-FTA-ABS test to show treponemal IgM in patients with untreated syphilis,⁷ and Johnston used it on cord and neonatal sera when infection of T pallidum was suspected.⁸ This test has not been widely used, however, because of the incidence of false positive and negative reactions and technical difficulties.⁹⁻¹² Müller and Oelerich gel filtrated patients serum and fractionated the IgM and IgG.¹³ Examination of these fractions by the TPHA and FTA-ABS tests showed six patterns reflecting stages of syphilis according to the amounts of treponemal IgM and IgG. Schmidt reported the solid phase haemadsorption assay (SPHA) for the rapid detection of treponemal IgM, using the surface of a microplate well.¹⁴ According to Müller and Lindenschmidt, however, the SPHA, which was associated with a high rate of false negative results in patients with untreated syphilis, did not correlate with the 19S(IgM)-FTA-ABS.¹⁵ Lindenschmidt and Müller investigated treponemal IgM and IgG by an enzyme linked immunosorbent assay (ELISA) with good results, and concluded that the ELISA should be a reliable tool for mass screening of syphilitic sera.¹⁶

This paper presents the TP-IgM-HA test, which is easy to perform and does not require special apparatus to detect treponemal IgM. We performed comparative tests for antibodies in 82 serum samples from 82 patients with untreated syphilis and 521 samples from 73 patients with treated syphilis using the 19S(IgM)-TPHA, 7S(IgG)-TPHA, IgM-FTA-ABS, IgG-FTA-ABS, TP-IgM-ELISA, TPHA, Venereal Diseases Research Laboratory (VDRL), RPR, CLCF, and TP-IgM-HA tests.

Address for reprints: Mr Takashi Sato, Third Department of Research Laboratories, Fujirebio Incorporation, 51 Komiya-cho, Hachioji-shi, Tokyo 192, Japan

Accepted for publication 24 February 1984
Material and methods

SYPHILITIC SERUM SAMPLES
We tested serum from 37 patients with untreated primary syphilis, 69 patients with secondary syphilis, 29 patients with late syphilis, 14 reinfected patients, and six patients with congenital syphilis. The clinical data were supplied by the Institute of Mandai Clinic in Osaka. An additional 1872 serum samples from patients who attended the same clinic but did not have syphilis were also examined.

FRACTIONATION OF SERUM BY GEL FILTRATION
A 0·35 ml sample of serum mixed with 0·65 ml of 0·08% blue dextran 2000 (Pharmacia) was fractionated on a SephadrylS-300 (Pharmacia Fine Chemicals, Sweden) column, 90 cm × 1·6 cm. The blue dextran was eluted in the void volume fractions of the column and almost in the same fractions as the IgM. Elution was performed with 0·5 mol/l sodium chloride solution containing 0·1% sodium azide. The flow rate was set at about 12 ml/hour, and every 2·5 ml fraction was collected. Optical absorbance at 280 nm of eluted fractions showed three peaks corresponding to IgM, IgG, and albumin fractions respectively. The separation of IgM from IgG was confirmed by the IgM-FTA-ABS, IgG-FTA-ABS, and turbidimetric immunoassay (N-TIA) (Nissui Pharmaceutical Co, Tokyo, Japan) tests, which indicated the presence of class specific antibodies only.

TPHA, IgM-FTA-ABS, IgG-FTA-ABS, VDRL, RPR, and CLCF TEST PROCEDURES
The TPHA, VDRL, and RPR tests were performed according to the instructions of the Japanese manufacturers (Fujirebio, Tokyo, and Kaketsukan, Kumamoto). The FTA-ABS test was performed with T pallidum (Nichols strain) as the antigen, and with sonicated T phagedenis (Reiter strain) as the sorbent.

Antihuman IgM rabbit serum (μ chain specific) labelled with fluorescein isothiocyanate (FITC) and antihuman IgG rabbit serum (γ chain specific) were supplied by Dako Immuunochemicals (Copenhagen, Denmark). The CLCF test was performed with the cardiolipin antigen (Sumitomo Chemical Co, Tokyo) according to the manufacturer's instructions.

TP-IgM-ELISA PROCEDURE
Poly styrene beads were coated with T pallidum antigen, washed with phosphate buffered saline (PBS), and stored at 4°C in PBS containing 0·1% bovine serum albumin (BSA) and 0·1% sodium azide for future use. A volume of 400 μl buffer (containing absorbent) was added to each tube and 5 μl of serum specimens and the beads coated with antigen were added. After incubation at 37°C for two hours, the beads were washed with saline. A volume of 400 μl conjugate (antihuman IgM) was added to each tube and incubated at 37°C for one hour. The excess conjugate was removed by washing with saline and 400 μl substrate buffer, containing 1 mmol/l hydrogen peroxide and 0·1% 2,2'-azino-(3-ethylbenzothiazoline-6-sulphonate), was then added and incubated at 37°C for one hour. The reaction was stopped by the addition of 2 ml 0·05 mol/l oxalic acid, and the absorbance was read at 420 nm. The cut off point between positive and negative was estimated as 1, which was the quotient of the absorbance at 420 nm divided by the positive control absorbance.

19S(IgM)-TPHA TEST PROCEDURE
After gel filtration of the serum, 24 fractions were obtained and tested quantitatively using Fujirebio TPHA reagents. The mean of the highest three titres in the IgM and IgG fractions was designated the 19S(IgM)-TPHA titre and 7S(IgG)-TPHA titre respectively.

PREPARATION OF TREPONEMAL ANTIGENS
Adult male New Zealand white rabbits were examined on receipt for clinical and serological evidence of T paraluiscuniculi infection. The testes of each rabbit were inoculated with 1 ml of 6 × 10⁷ cells/ml T pallidum suspension. After 11-13 days the testes were excised from each rabbit and minced. Testicular and red blood cells were removed by differential centrifugation, and the T pallidum organisms extracted were resuspended in PBS to 10⁹/ml. The organisms were disrupted by sonication (model UR-200P; Tomy Seiko Co, Japan) at 20 kHz for 10 minutes and after the addition of 0·01% thiomersal (Merthiolate) were stored at −70°C until further use.

PREPARATION OF CELLS SENSITISED WITH ANTIHUMAN IgM
Sheep red cells formalinised by the method described by Weinbach and Wide were suspended in PBS pH 6·4 at a concentration of 5% and mixed with an equal volume of 10 parts per million tannic acid solution. The mixture was incubated at 37°C for 10 minutes, and the cells washed twice with saline. Equal volumes of the cell suspension and an adequate dilution of the antihuman IgM in PBS pH 6·4 were mixed and incubated for 40 minutes at 37°C. The sensitised cells were washed twice with saline and resuspended in a suspension medium containing normal rabbit serum (NRS) and stabiliser. The suspended cells were pipetted into each vial, lyophilised, and stored at 4°C until used.
PREPARATION OF CELLS SENSITISED WITH T PALLIDUM

Cells sensitised with T. pallidum were prepared similarly to cells sensitised with antihuman IgM. T. pallidum disrupted by sonication was adequately diluted and mixed with an equal volume of a suspension of red cells that had been treated with tannic acid. After incubation at 37°C for 40 minutes the cells were washed twice with saline. The suspended cells were pipetted into vials, lyophilised, and stored at 4°C until used.

TP-IgM-HA PROCEDURE

A volume of 20 μl of serum samples was placed in the far left row of a round bottomed microtitration plate, and 80 μl of absorbing diluent containing gum arabic, Tween 80, NRS, and sonicated T. phagedenis (Reiter strain) was added to each sample (1/4 dilution). Seventy five μl of absorbing diluent was placed into each remaining well.

Lyophilised cells sensitized with antihuman IgM were reconstituted with distilled water, and 25 μl of the cell suspension was added to each well and mixed gently by hand or on a tray mixer. The plate was covered with another empty plate and incubated for 15 minutes at 37°C. The sensitised cells were then washed twice with saline (that is the plate was centrifuged, the supernatant aspirated, and the sensitised cells resuspended in saline). Finally, the cells were suspended in 25 μl of absorbing diluent. Lyophilised cells sensitised with T. pallidum were reconstituted with distilled water, and 25 μl of the cell suspension was added to each well and mixed gently by hand or on a tray mixer. The plate was left overnight without disturbance before reading the results. The patterns were read after two hours or the next day.

Results

SPECIFICITY OF TP-IgM-HA TEST

Table I shows that of 1712 serum samples from healthy people examined by the TP-IgM-HA method, four gave positive results at a dilution of 1/5, giving a false positive rate of 0.23%. Ninety one serum samples from patients with gastric cancer, pancreatic cancer, uterine cancer, and lung cancer were also examined by the TP-IgM-HA tests, and serum from one patient with gastric cancer gave a positive result. All 69 serum samples from patients with rheumatoid factor gave negative results in the TP-IgM-HA test. Of the 69 patients with rheumatoid factor, nine serum samples from three patients with adequately treated syphilis gave positive results in the IgM-FTA-ABS test but negative results in the TP-IgM-HA test. In total, five (0.3%) of the 1872 serum samples gave positive results in the TP-IgM-HA test.

The specificity of the TP-IgM-HA test was confirmed as follows: the serum samples from patients with untreated primary syphilis, which contained both treponemal IgM and IgG, were fractionated on a Sephacryl S-300 column and all 24 fractions were tested by the TPHA and TP-IgM-HA tests. The figure shows that the TPHA test reacted with both IgM and the IgG fractions but the TP-IgM-HA test reacted with IgM fractions only, which suggests that the TP-IgM-HA test detects only treponemal IgM.

Sensitivity of TP-IgM-HA Test

Table II shows the results of the TP-IgM-HA test on 82 serum samples giving positive results to the 19S(IgM)-TPHA test from patients with untreated primary and secondary syphilis. With one exception, 37 serum samples from patients with untreated primary syphilis that gave positive results to the 19S(IgM)-TPHA test also gave positive results to the TP-IgM-HA test. The one exception gave weakly positive results in the 19S(IgM)-TPHA test and borderline results in the IgM-FTA-ABS test, but gave negative results to the RPR and CLCF tests. With
one exception, 45 serum samples from patients with untreated secondary syphilis that gave positive results to the 19S(IgM)-TPHA test also gave positive results to the TP-IgM-HA test. The one exception gave negative results to the IgM-FTA-ABS and TP-IgM-ELISA tests.

Overall, the sensitivity of the TP-IgM-HA test in untreated primary and secondary syphilis was 97.6%.

**TABLE II** Sensitivity of the TP-IgM-HA test in serum samples from patients with untreated primary and secondary syphilis reactive in the 19S(IgM)-TPHA test

<table>
<thead>
<tr>
<th>Serum samples positive to 19S (IgM)-TPHA test from untreated patients with:</th>
<th>Results of TP-IgM-HA tests</th>
<th>Sensitivity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary (n = 37)</td>
<td>No positive at titres of: 1/5 1/20 1/80 1/320 1/1280</td>
<td>No (%)</td>
</tr>
<tr>
<td>10 12 9 4 1</td>
<td>1 (2.7)</td>
<td>97.3</td>
</tr>
<tr>
<td>Secondary (n = 45)</td>
<td>16 19 5 3 1</td>
<td>1 (2.2)</td>
</tr>
<tr>
<td>Total (n = 82)</td>
<td>26 31 14 7 2</td>
<td>2 (2.4)</td>
</tr>
</tbody>
</table>

**TABLE III** Comparison of antibody titres estimated by the 19S(IgM)-TPHA and TP-IgM-HA tests. As we expected, the results correlated well. Table IV compares antibody titres estimated by the IgM-FTA-ABS and TP-IgM-HA tests. They also correlated well.

Nine serum samples from patients with rheumatoid factor and five from patients who had been reinfected with *T. pallidum* showed irregular results. Table V compares antibody units and titres estimated by the TP-IgM-ELISA and TP-IgM-HA tests. Eight serum samples from patients reinjected with *T. pallidum* showed irregular results.

**CHANGES IN TP-IgM-HA TITRES AFTER TREATMENT**

One of the 108 serum samples from patients with adequately treated syphilis gave positive results to the TP-IgM-HA test and also in the 19S(IgM)-TPHA test.

Table VI shows the changes in the antibody titres and units to the nine tests before and after treatment with penicillin in two patients with primary syphilis. In the VDRL, CLCF, 19S(IgM)-TPHA, TP-IgM-ELISA, and TP-IgM-HA tests the antibody titre or unit decreased rapidly after treatment. In the TP-IgM-HA and IgM-FTA-ABS tests the titre changed to negative or borderline within four to five months.

**TABLE IV** Comparison of antibody titres in the TP-IgM-HA and IgM-FTA-ABS tests

<table>
<thead>
<tr>
<th>IgM-FTA-ABS test</th>
<th>Negative results</th>
<th>Positive results at titres of:</th>
<th>1/5</th>
<th>1/20</th>
<th>1/80</th>
<th>1/320</th>
<th>1/1280</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of serum samples giving:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative results</td>
<td>134</td>
<td>17</td>
<td>5*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>156</td>
</tr>
<tr>
<td>Borderline results (1/5 titre)</td>
<td>15</td>
<td>110</td>
<td>12</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td>139</td>
</tr>
<tr>
<td>Positive results at titres of:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1/20</td>
<td>9†</td>
<td>10</td>
<td>98</td>
<td>11</td>
<td>6</td>
<td></td>
<td></td>
<td>134</td>
</tr>
<tr>
<td>1/80</td>
<td>1</td>
<td>4</td>
<td>15</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td>26</td>
</tr>
<tr>
<td>1/320</td>
<td></td>
<td>1</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>1/1280</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>158</td>
<td>138</td>
<td>119</td>
<td>29</td>
<td>15</td>
<td>1</td>
<td></td>
<td>460</td>
</tr>
</tbody>
</table>

* Patients with reinfection.
† Patients with rheumatoid factor.
TABLE V  Comparison of TP-IgM-HA antibody titres and TP-IgM-ELISA antibody units

<table>
<thead>
<tr>
<th>TP-IgM-ELISA</th>
<th>Negative results</th>
<th>Positive results at titres of:</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of serum samples giving:</td>
<td>1/5</td>
<td>1/20</td>
</tr>
<tr>
<td>Negative results (units of 0-0.9)</td>
<td>44</td>
<td>8</td>
</tr>
<tr>
<td>Positive results at units of:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:1-9</td>
<td>11</td>
<td>45</td>
</tr>
<tr>
<td>2:2-9</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>3:3-9</td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>over 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>57</td>
<td>67</td>
</tr>
</tbody>
</table>

*Patients with reinfection.

On the other hand, in the 19S(IgM)-TPHA test a treponemal IgM of around 2 units was seen even five months after treatment.

Discussion

At present the IgM-FTA-ABS test is the most widely used method to identify *T pallidum* specific IgM antibodies. This method, however, produces incorrect results due to various factors in the serum such as excess quantities of *T pallidum* specific IgG, rheumatoid factor, *T pallidum* specific 8S IgM, and IgM-anti-IgG autoantibodies. Further cumbersome test procedures make mass assays troublesome and laborious.

While Schmidt used the wall of the microplate well, we used the surface of fixed sheep erythrocytes sensitised with antiserum to human IgM to extract IgM from the serum. A bonding between polystyrene, a material of the microplate, and the erythrocytes sensitised with rabbit antiserum to human IgM is the result of hydrophobic adherence. Thus, the erythrocytes sensitised with rabbit antiserum to human IgM are easily dissociated by washing or combination with the erythrocytes sensitised with purified *T pallidum*. For this reason considerable variations in the titre depend on the method of washing and on the concentration of the erythrocytes sensitised with purified *T pallidum*. In contrast, when the erythrocytes are sensitised with rabbit antiserum to human IgM with tannic acid, it becomes a strong bonding agent mediated by a covalent bond. Accordingly, in the TP-IgM-HA test the frequency of washing or the concentration of the erythrocytes sensitised with purified *T pallidum* is of little importance. Moreover, when fewer than 24 samples are tested all the test procedures are completed within two hours, and results are available two hours later.

TABLE VI  Comparison of the TP-IgM-HA titres with other serological test titres and units after treatment of patients with primary syphilis

<table>
<thead>
<tr>
<th>Time after treatment</th>
<th>VDRL</th>
<th>CLCF</th>
<th>TPHA</th>
<th>19S(IgM)-TPHA</th>
<th>7S(IgG)-TPHA</th>
<th>IgM-FTA-ABS</th>
<th>IgG-FTA-ABS</th>
<th>TP-IgM-ELISA</th>
<th>TP-IgM-HA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1 (female)</td>
<td>0</td>
<td>1/32</td>
<td>1/320</td>
<td>1/80</td>
<td>1/10-2</td>
<td>*</td>
<td>1/80</td>
<td>*</td>
<td>3-2</td>
</tr>
<tr>
<td>5 days</td>
<td>1/64</td>
<td>1/640</td>
<td>1/80</td>
<td>1/16-0</td>
<td>*</td>
<td>*</td>
<td>1/20</td>
<td>1/5</td>
<td>3-3</td>
</tr>
<tr>
<td>19 days</td>
<td>1/32</td>
<td>1/160</td>
<td>1/80</td>
<td>1/16-0</td>
<td>*</td>
<td>*</td>
<td>1/20</td>
<td>1/20</td>
<td>2-9</td>
</tr>
<tr>
<td>1 month</td>
<td>1/8</td>
<td>1/80</td>
<td>1/80</td>
<td>1/8-3</td>
<td>*</td>
<td>*</td>
<td>1/20</td>
<td>1/20</td>
<td>2-3</td>
</tr>
<tr>
<td>2 months</td>
<td>1/4</td>
<td>1/160</td>
<td>1/320</td>
<td>1/4-0</td>
<td>1/2-8</td>
<td>1/20</td>
<td>1/80</td>
<td>1/7</td>
<td>1/20</td>
</tr>
<tr>
<td>4 months</td>
<td>1/2</td>
<td>1/10</td>
<td>1/320</td>
<td>1/3-3</td>
<td>1/5-9</td>
<td>1/20</td>
<td>1/80</td>
<td>1/6</td>
<td>1/5</td>
</tr>
<tr>
<td>5 months</td>
<td>*</td>
<td>*</td>
<td>1/320</td>
<td>1/2-1</td>
<td>1/5-2</td>
<td>1/5</td>
<td>1/80</td>
<td>(0-9)*</td>
<td>*</td>
</tr>
<tr>
<td>Case 2 (male)</td>
<td>0</td>
<td>1/16</td>
<td>1/640</td>
<td>1/160</td>
<td>1/32-3</td>
<td>*</td>
<td>*</td>
<td>1/320</td>
<td>4-4</td>
</tr>
<tr>
<td>2 weeks</td>
<td>1/32</td>
<td>1/640</td>
<td>1/80</td>
<td>1/25-7</td>
<td>*</td>
<td>1/5</td>
<td>1/320</td>
<td>4-0</td>
<td>1/320</td>
</tr>
<tr>
<td>1 month</td>
<td>1/8</td>
<td>1/640</td>
<td>1/80</td>
<td>1/16-6</td>
<td>*</td>
<td>1/5</td>
<td>1/80</td>
<td>3-5</td>
<td>1/320</td>
</tr>
<tr>
<td>2 months</td>
<td>1/4</td>
<td>1/160</td>
<td>1/80</td>
<td>1/3-6</td>
<td>1/0-5</td>
<td>1/20</td>
<td>1/80</td>
<td>2-4</td>
<td>1/80</td>
</tr>
<tr>
<td>3 months</td>
<td>1/2</td>
<td>1/80</td>
<td>1/80</td>
<td>1/3-6</td>
<td>1/3-3</td>
<td>1/80</td>
<td>1/5</td>
<td>1/5</td>
<td>1/5</td>
</tr>
<tr>
<td>4 months</td>
<td>1/1</td>
<td>1/20</td>
<td>1/80</td>
<td>1/4-0</td>
<td>1/4-0</td>
<td>1/5</td>
<td>1/20</td>
<td>(0-8)*</td>
<td>*</td>
</tr>
<tr>
<td>5 months</td>
<td>*</td>
<td>*</td>
<td>1/80</td>
<td>1/2-0</td>
<td>1/5-1</td>
<td>*</td>
<td>1/20</td>
<td>(0-6)*</td>
<td>*</td>
</tr>
</tbody>
</table>

VDRL = Venereal Diseases Research Laboratory test; CLCF = complement fixation with cardiolipin antigen test; TPHA = *Treponema pallidum* haemagglutination assay; FTA-ABS = fluorescent treponemal antibody absorption test; ELISA = enzyme linked immunosorbent essay. * = negative reaction.
Treponema pallidum specific IgM haemagglutination test for serodiagnosis of syphilis

The specificity of the TP-IgM-HA test was 99.7%. All serum containing rheumatoid factor gave negative results to the test. The five false positive serum samples were gel filtrated on a Sephacryl S-300 column and separated into IgM and IgG fractions. The IgM fractions gave positive results but the IgG fractions negative results to the TP-IgM-HA test. It was recognised that the false positive non-specific factor was associated with the 19S(IgM) class. The sensitivity of the TP-IgM-HA test serum samples from patients with untreated primary and secondary syphilis was 97.3% and 97.8% respectively. Overall, the sensitivity of the TP-IgM-HA test in untreated primary and secondary syphilis was 97.6%. Unfortunately we could not obtain serum samples from patients with untreated late latent syphilis. The antibody titre results of the 19S(IgM)-TPHA and the TP-IgM-HA tests showed a good correlation (table III). Twenty five of the serum samples giving positive results to the 19S(IgM)-TPHA and the TP-IgM-HA tests gave negative reactions to the IgM-FTA-ABS test. Of the nine 19S(IgM)-TPHA positive serum samples from patients who had been reinfected with syphilis, one gave negative reactions to the TP-IgM-HA and the IgM-FTA-ABS tests and the other eight gave positive reactions to the TP-IgM-HA test.

The antibody titres estimated by the TP-IgM-HA and the IgM-FTA-ABS tests also correlated well (table IV). All nine serum samples that gave positive results to the IgM-FTA-ABS test and negative results to the TP-IgM-HA test contained rheumatoid factor. We assumed these serum samples gave false positive reactions to the IgM-FTA-ABS test due to the presence of rheumatoid factor. All five serum samples that gave negative results to the IgM-FTA-ABS test and positive results to the TP-IgM-HA test (at a serum dilution of 1/20) were from reinfected patients. All of these reinfected serum samples showed high titres to the TPHA and FTA-ABS tests. Presumably a false negative result may occur by competitive inhibition between excess treponemal IgG and deficient treponemal IgM on the surface of T pallidum.

The TP-IgM-HA and TP-IgM-ELISA tests (table V) also correlated well. Eight sera from reinfected patients gave positive results to the TP-IgM-HA test but negative results to the TP-IgM-ELISA test. Five serum samples from reinfected patients gave negative results to the IgM-FTA-ABS test. The TP-IgM-ELISA and IgM-FTA-ABS tests are based on similar techniques—that is, all classes of treponemal antibodies in the specimen may be associated with the T pallidum antigen, and the treponemal IgM is detected by the labelled antihuman IgM. Excess treponemal IgG, however, disturbs the attachment of the treponemal IgM to the surface of the T pallidum antigen. As a result, a false negative result occasionally occurs in reinfected patients.

One of the 108 serum samples from adequately treated patients gave positive results to the TP-IgM-HA test; treponemal IgM was also detected in the 19S(IgM)TPHA, IgM-FTA-ABS, TP-IgM-ELISA tests in the case of treated serum samples. We therefore assumed that treponemal IgM continues to exist in the patient for some reason despite adequate treatment. A 62 year old man had been treated inadequately with arsphenamine (salvarsan). Twenty years later he was given penicillin treatment, but the treponemal IgM did not decrease. Further investigations and discussions are necessary to ascertain the reason for this.

We believe that the TP-IgM-HA test, which can easily detect treponemal IgM in a short time and has high specificity and high sensitivity in detecting treponemal IgM, will be a most effective tool in obtaining information on the necessity and monitoring of treatment of syphilis.

We thank Professor Z Yoshii of Ube University, the late Dr Y Nakamizo, and Dr M Fukuyama for their valuable guidance. We also thank Dr H Tsugami and K Matsunaga of the Institute of Mandai Clinic, Osaka, for providing specimens and valuable data.

References


Treponema pallidum specific IgM haemagglutination test for serodiagnosis of syphilis.

T Sato, E Kubo, M Yokota, T Kayashima and T Tomizawa

Br J Vener Dis 1984 60: 364-370
doi: 10.1136/sti.60.6.364

Updated information and services can be found at:
http://sti.bmj.com/content/60/6/364

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/